SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001641489-23-000062
Filing Date
2023-11-01
Accepted
2023-11-01 08:24:55
Documents
14
Period of Report
2023-10-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vtvt-20231030.htm   iXBRL 8-K 27538
2 EX-99.1 vtvt-20231101xexx991pressr.htm EX-99.1 14094
6 GRAPHIC vtvv_outlinexcolorxnotagli.jpg GRAPHIC 116073
  Complete submission text file 0001641489-23-000062.txt   324384

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vtvt-20231030.xsd EX-101.SCH 1913
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vtvt-20231030_lab.xml EX-101.LAB 23834
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vtvt-20231030_pre.xml EX-101.PRE 12516
8 EXTRACTED XBRL INSTANCE DOCUMENT vtvt-20231030_htm.xml XML 2829
Mailing Address 3980 PREMIER DR SUITE 310 HIGH POINT NC 27265
Business Address 3980 PREMIER DR SUITE 310 HIGH POINT NC 27265 336-841-0300
vTv Therapeutics Inc. (Filer) CIK: 0001641489 (see all company filings)

IRS No.: 473916571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37524 | Film No.: 231366656
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences